BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 13, 2024
See today's BioWorld Asia
Home
» Regulatory actions for Jan. 17-30, 2023
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Regulatory actions for Jan. 17-30, 2023
Jan. 31, 2023
No Comments
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Abbisko, Amarin, Ascletis, Astellas, Astrazeneca, Axcella, Beigene, Carina, Daewoong, Daiichi Sankyo, Duality, Eisai, Genexine, Harbour Biomed, Henlius, Hutchmed, Immunos, Immuron, Junshi, Luye, Neuren, Novavax, Paratek, Pfizer, Revive, Sinopharm, Sofie, Specialised, Takeda, Valeo, Yantai LNC.
BioWorld Asia
Briefs
Regulatory actions